Efficacy of pegylated-liposomal doxorubicin in the treatment of AIDS-related Kaposi's sarcoma after failure of standard chemotherapy.
Donald W. Northfelt(Mayo Clinic in Arizona), Richard D. Mamelok(Johnson & Johnson (United States)), Richard G. Levine(Johnson & Johnson (United States)), Clément Dumond(Johnson & Johnson (United States)), A Ríos(Johnson & Johnson (United States)), James Thommes(Johnson & Johnson (United States)), Jamie H. Von Roenn(American Society of Clinical Oncology), Bruce J. Dezube(Xilio Therapeutics (United States)), Susan E. Krown(Memorial Sloan Kettering Cancer Center), Gary M. Dosik(Johnson & Johnson (United States))
Cited by 170
Related Papers
Kaposi sarcoma
|Nature Reviews Disease Primers|2019|707
Kaposi's sarcoma in the acquired immune deficiency syndrome: a proposal for uniform evaluation, response, and staging criteria. AIDS Clinical Trials Group Oncology Committee.
|Journal of Clinical Oncology|1989|483
Preliminary Observations on the Effect of Recombinant Leukocyte a Interferon in Homosexual Men with Kaposi's Sarcoma
|New England Journal of Medicine|1983|358
Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer
|Nature Communications|2020|342